OPEN END-TURBO-OPTIONSSCHEIN - GILEAD SCIENCES | Real-time BOERSE MUENCHEN 07:01:47 17/06/2024 BST | ||
| 7.94 EUR | +3.12% |
|
| Current month | +22.22% | ||
| 1 month | -23.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 7.94 | +3.12% |
| 14/06/24 | 7.7 | +25.41% |
| 13/06/24 | 6.14 | -3.46% |
| 12/06/24 | 6.36 | -8.88% |
| 11/06/24 | 6.98 | -4.64% |
Real-time BOERSE MUENCHEN
Last update June 17, 2024 at 07:01 am
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | HSBC |
| WKN | TT4Q9H |
| ISIN | DE000TT4Q9H8 |
| Date issued | 11/11/2020 |
| Strike | 56.74 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 5.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.72 € |
|---|---|
| Lowest since issue | 4 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.06
USD
Average target price
82.7
USD
Spread / Average Target
+27.11%
- Stock Market
- Certificates
- Certificat